Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma
22. Februar 2022 08:00 ET
|
Triphase Accelerator
High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable safety profile: AEs predominantly low grade, tolerable, easily managed, and...
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
07. Dezember 2020 16:30 ET
|
Triphase Accelerator
TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
01. April 2019 08:00 ET
|
Triphase Accelerator
Toronto, Ontario, and Somerset, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of...
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
29. Januar 2019 07:00 ET
|
Triphase Accelerator
TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class...
Triphase Accelerator to Present Investigational New Drug Enabling Data for TRPH-222
04. Dezember 2017 17:35 ET
|
Triphase Accelerator
TORONTO and SOMERSET, N.J., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and...
Triphase Accelerator Reports Completion of Initial Regulatory Interactions with FDA and Health Canada for TRPH-222 for the Treatment of Lymphoma
01. Mai 2017 09:32 ET
|
Triphase Accelerator
TORONTO and SAN DIEGO, May 01, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...
Triphase Accelerator Announces New Collaboration with Celgene Corporation for TRPH-222, an anti-CD22 Antibody Drug Conjugate
21. Dezember 2016 09:30 ET
|
Triphase Accelerator
TORONTO and SAN DIEGO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...
Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma
18. November 2016 17:50 ET
|
Triphase Accelerator
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma TORONTO and SAN DIEGO, Nov. 18, 2016 (GLOBE...
Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation
17. November 2016 20:20 ET
|
Triphase Accelerator
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma. TORONTO and SAN DIEGO, Nov. 17, 2016 (GLOBE...
Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic
04. Oktober 2016 08:30 ET
|
Triphase Accelerator; Catalent
SOMERSET, N.J. and LA JOLLA, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and...